Recent changes

Jump to: navigation, search

Track the most recent changes to the wiki on this page.

Recent changes options
Legend:
N
This edit created a new page (also see list of new pages)
m
This is a minor edit
b
This edit was performed by a bot
(±123)
The page size changed by this number of bytes
Show last 50 | 100 | 250 | 500 changes in last 1 | 3 | 7 | 14 | 30 days
Hide minor edits | Show bots | Hide anonymous users | Hide registered users | Hide my edits
Show new changes starting from 21:59, 28 June 2017
   

27 June 2017

     22:04  Acute promyelocytic leukemia‎‎ (2 changes | history) . . (+10,029)‎ . . [Jwarner‎ (2×)]
      22:04 (cur | prev) . . (+8,438)‎ . . Jwarner (talk | contribs)
 m    20:47 (cur | prev) . . (+1,591)‎ . . Jwarner (talk | contribs) (→‎ATRA, Cytarabine, Daunorubicin {{#subobject:dade93|Regimen=1}})
     22:02  Acute myeloid leukemia‎‎ (3 changes | history) . . (+2,333)‎ . . [Jwarner‎ (3×)]
 m    22:02 (cur | prev) . . (+32)‎ . . Jwarner (talk | contribs) (→‎Regimen {{#subobject:f9ef00|Variant=1}})
 m    22:01 (cur | prev) . . (+30)‎ . . Jwarner (talk | contribs) (→‎Regimen #1 {{#subobject:12351c|Variant=1}})
      22:01 (cur | prev) . . (+2,271)‎ . . Jwarner (talk | contribs) (→‎Clofarabine & Cytarabine {{#subobject:7a3edd|Regimen=1}})
     15:15  Castleman disease‎‎ (5 changes | history) . . (+4,667)‎ . . [Dfajgenbaum‎ (5×)]
      15:15 (cur | prev) . . (+330)‎ . . Dfajgenbaum (talk | contribs) (→‎HHV-8-negative/"Idiopathic" Multicentric Castleman’s disease) (Tag: Visual edit)
      15:13 (cur | prev) . . (+328)‎ . . Dfajgenbaum (talk | contribs) (→‎HHV-8-negative/"Idiopathic" Multicentric Castleman’s disease) (Tag: Visual edit)
      15:10 (cur | prev) . . (+772)‎ . . Dfajgenbaum (talk | contribs) (→‎Rituximab) (Tag: Visual edit)
      15:04 (cur | prev) . . (+2,172)‎ . . Dfajgenbaum (talk | contribs) (added treatments) (Tag: Visual edit)
      14:48 (cur | prev) . . (+1,065)‎ . . Dfajgenbaum (talk | contribs) (changes to treatments) (Tag: Visual edit)

26 June 2017

 m   23:37  Multiple myeloma‎‎ (4 changes | history) . . (+2,308)‎ . . [Jwarner‎ (4×)]
 m    23:37 (cur | prev) . . (+712)‎ . . Jwarner (talk | contribs) (→‎References)
 m    23:34 (cur | prev) . . (+716)‎ . . Jwarner (talk | contribs) (→‎References)
 m    23:29 (cur | prev) . . (+896)‎ . . Jwarner (talk | contribs) (→‎Melphalan -> autologous hematopoietic cell transplant {{#subobject:149d91|Regimen=1}})
 m    22:36 (cur | prev) . . (-16)‎ . . Jwarner (talk | contribs) (→‎Outdated)
 m   23:20  Multiple myeloma - obsolete‎‎ (4 changes | history) . . (+5,803)‎ . . [Jwarner‎ (4×)]
 m    23:20 (cur | prev) . . (+545)‎ . . Jwarner (talk | contribs) (→‎Melphalan (Alkeran) {{#subobject:79b2d2|Regimen=1}})
 m    23:14 (cur | prev) . . (+488)‎ . . Jwarner (talk | contribs) (→‎References)
 m    23:09 (cur | prev) . . (+4,158)‎ . . Jwarner (talk | contribs) (→‎VBMCP {{#subobject:7bd579|Regimen=1}})
 m    22:59 (cur | prev) . . (+612)‎ . . Jwarner (talk | contribs) (→‎References)
 m   23:01  Transplant conditioning regimens‎ (diff | hist) . . (-2)‎ . . Jwarner (talk | contribs) (→‎VMCP & BVAP -> high-dose Melphalan (Alkeran) {{#subobject:fdb3f3|Regimen=1}})

25 June 2017

 m   23:21  HemOnc.org - A Hematology Oncology Wiki:General disclaimer‎ (diff | hist) . . (+23)‎ . . PeterYang (talk | contribs)
 m   21:52  Diffuse large B-cell lymphoma - obsolete‎ (diff | hist) . . (+1,060)‎ . . Jwarner (talk | contribs) (→‎DHAP {{#subobject:cd4f8f|Regimen=1}})
     21:33  Diffuse large B-cell lymphoma‎‎ (6 changes | history) . . (+4,228)‎ . . [Jwarner‎ (6×)]
      21:33 (cur | prev) . . (+821)‎ . . Jwarner (talk | contribs) (→‎Blinatumomab (Blincyto) {{#subobject:4c5004|Regimen=1}})
 m    21:20 (cur | prev) . . (+1,019)‎ . . Jwarner (talk | contribs) (→‎References)
 m    21:19 (cur | prev) . . (-726)‎ . . Jwarner (talk | contribs) (→‎Observation)
 m    21:18 (cur | prev) . . (+568)‎ . . Jwarner (talk | contribs) (→‎Autologous hematopoietic cell transplant {{#subobject:fccfc5|Regimen=1}})
 m    21:06 (cur | prev) . . (+1,016)‎ . . Jwarner (talk | contribs) (→‎Observation)
      21:04 (cur | prev) . . (+1,530)‎ . . Jwarner (talk | contribs) (→‎Methotrexate (MTX) {{#subobject:d77e3a|Regimen=1}})
     21:28  Transplant conditioning regimens‎‎ (2 changes | history) . . (+2,439)‎ . . [Jwarner‎ (2×)]
      21:28 (cur | prev) . . (+1,274)‎ . . Jwarner (talk | contribs) (→‎TAM6 {{#subobject:c810fd|Regimen=1}})
 m    21:24 (cur | prev) . . (+1,165)‎ . . Jwarner (talk | contribs) (→‎CBV {{#subobject:935235|Regimen=1}})
     15:04  Non-small cell lung cancer‎ (diff | hist) . . (+4,875)‎ . . Jwarner (talk | contribs)
 m   14:03  Sarcoma‎‎ (2 changes | history) . . (+2,030)‎ . . [Jwarner‎ (2×)]
 m    14:03 (cur | prev) . . (+834)‎ . . Jwarner (talk | contribs) (→‎Placebo)
 m    14:01 (cur | prev) . . (+1,196)‎ . . Jwarner (talk | contribs) (→‎Trabectedin (Yondelis) {{#subobject:cfc3ed|Regimen=1}})

24 June 2017

     22:49  Sarcoma‎‎ (2 changes | history) . . (+1,818)‎ . . [Jwarner‎ (2×)]
 m    22:49 (cur | prev) . . (+26)‎ . . Jwarner (talk | contribs) (→‎Doxorubicin (Adriamycin) {{#subobject:826f82|Regimen=1}})
      22:36 (cur | prev) . . (+1,792)‎ . . Jwarner (talk | contribs) (→‎Single-agent regimens)
 m   22:45  Professional organizations‎ (diff | hist) . . (+92)‎ . . Jwarner (talk | contribs)
 m   22:44  Central nervous system (CNS) cancer‎ (diff | hist) . . (+986)‎ . . Jwarner (talk | contribs) (→‎ESMO)
 m   22:23  Ovarian cancer‎ (diff | hist) . . (+816)‎ . . Jwarner (talk | contribs) (→‎Carboplatin & Paclitaxel {{#subobject:f8f27a|Regimen=1}})

23 June 2017

 m   22:11  Non-small cell lung cancer‎‎ (7 changes | history) . . (+3,822)‎ . . [Jwarner‎ (7×)]
 m    22:11 (cur | prev) . . (+36)‎ . . Jwarner (talk | contribs) (→‎References)
 m    22:08 (cur | prev) . . (+681)‎ . . Jwarner (talk | contribs) (→‎References)
 m    22:07 (cur | prev) . . (+671)‎ . . Jwarner (talk | contribs) (→‎References)
 m    22:07 (cur | prev) . . (+671)‎ . . Jwarner (talk | contribs) (→‎References)
 m    22:06 (cur | prev) . . (+671)‎ . . Jwarner (talk | contribs) (→‎References)
 m    21:42 (cur | prev) . . (-14)‎ . . Jwarner (talk | contribs) (→‎Placebo (Observation) {{#subobject:6ab28b|Regimen=1}})
 m    21:36 (cur | prev) . . (+1,106)‎ . . Jwarner (talk | contribs) (→‎Nivolumab (Opdivo) {{#subobject:PYR1|Regimen=1}})
     14:34  Venous thromboembolism (VTE)‎ (diff | hist) . . (+965)‎ . . Jwarner (talk | contribs) (→‎Treatments)
N    14:28  Betrixaban (Bevyxxa)‎‎ (3 changes | history) . . (+1,607)‎ . . [Jwarner‎ (3×)]
 m    14:28 (cur | prev) . . (-25)‎ . . Jwarner (talk | contribs)
 m    14:28 (cur | prev) . . (+33)‎ . . Jwarner (talk | contribs) (→‎Diseases for which it is used)
N     14:27 (cur | prev) . . (+1,599)‎ . . Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism: Direct factor Xa inhibitor. By inhibiting free and clotbound factor Xa in the coagulation cascade, betrixaban inhibits prothrombinase...")
 m   14:22  Drug index‎ (diff | hist) . . (+1)‎ . . Jwarner (talk | contribs) (→‎B)
 m   11:35  External links‎ (diff | hist) . . (+76)‎ . . Jwarner (talk | contribs) (→‎Diagnosis)
Retrieved from "https://hemonc.org/wiki/Special:RecentChanges"